| Management target | Revenue FY27 |
|---|
| Revenue growth | Volume-led growth; COVID contributed 25% of recent revenue. |
|---|---|
| Margins | Healthy 29-30% margins driven by fixed doctor salaries and high occupancy. |
| Demand visibility | Strong domestic demand; international patient share remains low at <1%. |
| Management confidence | Balanced and conservative regarding long-term margin sustainability during expansion. |
Growth
Revenue growth is volume-led with 25% contribution from high-margin COVID-related cases and insurance/cash mix.
Outlook
Management targets 1.25x revenue on ₹100 crore capex with 20-25% EBITDA within 3-5 years post-maturation.
Risks
Margins face dilution risk as heavy capex in Chennai and Bangalore comes online in 2-3 years.
Last quarter's promises, checked
Delivered
- Guided Thane EBITDA break-even by March → Delivered Neutral (= BEAT)
- Guided 10,000 brain tumor surgeries milestone → Delivered 10,000+ (= BEAT)
- Guided Kondapur expansion to 800 beds → Delivered Phase 1 commissioning June (= BEAT)
Partly delivered
- Guided debt peaking out → Delivered ₹3,000cr+ with QIP needed to retire ₹1,000cr (= PARTIAL)
- Guided insurance empanelment → Delivered 70% in Thane but Bangalore delayed 3-4 months (= PARTIAL)
Missed
- Guided PAT ₹106cr (Q4FY25) → Delivered ₹33cr (= MISS)
- Guided EPS growth → Delivered -37.2% YoY (= MISS)
- Guided EBITDA margin 25.3% (Q4FY25) → Delivered 19.9% (= MISS)
Earnings Call Transcript filed with BSE, NSE: KIMS. Summary written with AI assistance from the document.
Krishna Institute of Medical Sciences Ltd: key numbers
- Share price
- ₹780.15
- Market cap
- ₹32,767 Cr
- Revenue (annual)
- ₹3,905 Cr
- Net profit (annual)
- ₹241.4 Cr
- P/E (TTM)
- 160.4×Sector 57.8×
- Promoter holding
- 32.50%-1.61% QoQ
- FII holding
- 14.75%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krishna Institute of Medical Sciences Ltd
All →Krishna Institute of Medical Sciences Share Pledge
Promoters pledged 2,80,08,979 equity shares (6.66%) to Catalyst Trusteeship as debenture trustee. The pledge secures existing debenture obligations with no new capital involved.
Krishna Institute of Medical Sciences Capacity Expansion
Krishna Institute of Medical Sciences Ltd entered an Operations and Management Agreement with Sarvottam Health Care Pvt Ltd for 5+5 years to manage their operations.
- Execution
- 5 years with an extension for a further period of 5 years
Krishna Institute of Medical Sciences Investor Presentation: Key Takeaways
KIMS reported strong Q1 FY27 results with consolidated operating revenue growth of 35.3% YoY and 9.8% QoQ, driven by expansion and higher occupancy in core clusters.
Krishna Institute of Medical Sciences Q1 FY27 Results: Net Profit ₹37.4 Cr, Down 56.0% YoY
Krishna Institute of Medical Sciences Ltd reported revenue from operations of ₹1,180 Cr (+35.3% YoY) and net profit of ₹37.4 Cr (-56.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹37.4 Cr · -56.0% YoY
Krishna Institute of Medical Sciences Earnings Call: Key Takeaways
KIMS Hospitals Q4 FY26 earnings call highlighting robust 35.3% revenue growth to INR 1,084cr, despite EBITDA margin contraction to 19.9% due to heavy expansion and new unit drags.
Krishna Institute of Medical Sciences Earnings Call: Key Takeaways
KIMS delivered FY26 revenue growth of 28.2% YoY, reaching ₹39,308 Mn. Expansion continues across Telangana, AP, Maharashtra, and Kerala with a vision to reach 8600+ beds.